Calidi Biotherapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
CLDI$0.68-6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| (Unaudited) | ||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(10,823) | $(12,992) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 801 | 752 |
| Amortization of debt discount and financing costs | — | 32 |
| Stock-based compensation | 1,129 | 1,639 |
| Change in fair value of debt, other liabilities and derivatives | (16) | 104 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (156) | 1,582 |
| Accounts payable | (733) | 1,142 |
| Accrued expenses and other current liabilities | (1,449) | (1,095) |
| Operating lease right of use liability | (764) | (489) |
| Net cash used in operating activities | (12,011) | (9,325) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of machinery and equipment | (64) | (5) |
| Net cash used in investing activities | (64) | (5) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from public offerings | 6,573 | 5,406 |
| Proceeds from Registered Direct Offering | 3,503 | — |
| Proceeds from exercise of pre-funded warrants | 3 | 2 |
| Repayment of principal on related party term notes payable | (1,625) | — |
| Payment of financing costs | (381) | (781) |
| Repayment of principal on term notes payable | (200) | (300) |
| Repayment of principal on related party bridge loan payable | (200) | — |
| Repayment of financing lease obligations | (34) | (45) |
| Proceeds from warrant inducement financing | — | 2,140 |
| Proceeds from exercise of common stock warrants | — | 100 |
| Related party proceeds from issuance of loan payable | — | 200 |
| Proceeds from issuance of convertible notes payable | — | 3,000 |
| Repayment of convertible note payable | — | (1,500) |
| Payment of debt issuance costs | — | (9) |
| Net cash provided by financing activities | 7,639 | 8,213 |
| Effect of exchange rate changes on cash | 6 | 4 |
| NET DECREASE IN CASH AND RESTRICTED CASH | (4,430) | (1,113) |
| CASH AND RESTRICTED CASH BALANCE: | ||
| At beginning of the period | 9,809 | 2,167 |
| At end of the period | $5,379 | $1,054 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid for interest | $837 | $116 |
| Cash paid for income taxes | $7 | $6 |
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES | ||
| Machinery and equipment acquired through financing leases | $152 | $— |
| Issuance of common stock in lieu of cash for services | $— | $29 |
| Issuance of common stock in lieu of cash for SEPA commitment fee | $— | $81 |
| Issuance of warrants for legal settlement | $— | $158 |
| Issuance of convertible note for legal settlement | $— | $1,500 |
| Financing fees included in accounts payable and accrued liabilities | $— | $560 |
| Discount on convertible note payable | $— | $149 |
| Deemed dividend on warrants | $— | $1,671 |
| Issuance of common stock per conversion of convertible note | $— | $1,028 |
| Issuance of RSUs for liability settlement | $— | $105 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.